Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.36 |
| ▸ | RAB9A | P51151 | 4/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.36 |
| ▸ | RELA | Q04206 | 2/20 | 0.36 |
| ▸ | HPGDS | O60760 | 11/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.30 |
| ▸ | KDR | P35968 | 1/20 | 0.30 |
| ▸ | FLT3 | P36888 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14725779 | 0.82 | CYP11B1 (0.48) | — | |
| SCHEMBL14725775 | 0.80 | NPC1 (0.36) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL20228674 | 0.80 | MEN1 (0.40) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL20228595 | 0.80 | MEN1 (0.37) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL14725773 | 0.79 | PDK2 (0.42) | — | |
| SCHEMBL20228722 | 0.79 | MEN1 (0.39) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL15461872 | 0.79 | CYP11B1 (0.47) | — | |
| SCHEMBL14725790 | 0.77 | KDM4E (0.31) | MAPT | |
| SCHEMBL14727507 | 0.76 | ABL1 (0.42) | NPC1RAB9ALMNAMAPT | |
| SCHEMBL17206414 | 0.75 | MEN1 (0.38) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9255084-B2 | Heterocyclic compound and organic light-emitting device containing the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2016-02-09 | — | — | US | disclosed |
| US-20130048955-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE CONTAINING THE SAME | SAMSUNG MOBILE DISPLAY CO., LTD. (KR) | 2013-02-28 | — | — | US | disclosed |
| US-20130048955-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE CONTAINING THE SAME | SAMSUNG MOBILE DISPLAY CO., LTD. (KR) | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130048955-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE CONTAINING THE SAME | TRPC1, TRPC4, TRPC6 | NPC1 1953/4885RAB9A 1964/4885SMN1; SMN2 1873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.